This episode reviews cases of steroid-induced laminitis and examines recent research and owner-reported experiences using SGLT2 inhibitors (most commonly ertugliflozin) as an off-label treatment for equine metabolic syndrome and hyperinsulinemia-associated laminitis.
An online survey of 342 owners found most horses treated with SGLT2Is showed improved quality of life and reduced pain, with many horses spared from euthanasia; common initial side effects included increased drinking and urination, weight loss, and dullness, which were often dose-dependent or resolved over time.
Key takeaways: SGLT2Is show promise as a rescue option for laminitis when combined with strict dietary management and good hoof care, but long-term safety, availability, cost, and further research remain important considerations.
Podden och tillhörande omslagsbild på den här sidan tillhör
Nancy McLean. Innehållet i podden är skapat av Nancy McLean och inte av,
eller tillsammans med, Poddtoppen.
